Genome Therapeutics Corp. and ICAgen, Inc. have announced an agreement that utilizes Genome Therapeutics’ technology to facilitate the assessment and development of a clinical trial design protocol for one of ICAgen’s ion channel targets. The genomics technology utilizes polymorphism analysis in subgroups of the target patient population to rapidly determine the target’s efficacy and thus Read more about Genome Therapeutics And ICAgen Collaborate To Conduct Drug Target Analysis[…]